Prognostic Markers in Pediatric Critical Care: Data From the Diverse Majority*

Michael J. Carter,Suchitra Ranjit
DOI: https://doi.org/10.1097/pcc.0000000000003408
2024-03-06
Pediatric Critical Care Medicine
Abstract:In recent years, the stratification of adult critical illness into phenotypes with shared clinical features, and endotypes with shared biological mechanisms of disease, has gained traction ( 1 ). These developments fore-shadowed and followed an emphasis on sepsis in adults as a dysregulated host response to infection ( 2 ) in the Sepsis-3 definition ( 2 ), increased recognition of inflammation in noninfectious diseases ( 3 ), and co-opted "big" gene expression and clinical datasets ( 1 ). The COVID-19 pandemic further accelerated these efforts. With exceptions, childhood critical illness remains more amorphous: sepsis is still defined by measurement of the systemic inflammatory response syndrome (SIRS) that has little prognostic accuracy for predicting severe disease ( 4 , 5 ). The etiology of childhood pneumonia is stubbornly opaque to even the most thorough research ( 6 ). Trauma, malignancies, and postoperative critical illness are less numerous ( 7 ) and have until recently been considered as separate from critical illness caused by infection. In addition, less proximate causes of childhood mortality, including malnutrition and complications of prematurity have been placed within the rubric of public health. Despite these challenges, severity scoring for childhood illness has progressed with the development of age-adjusted sequential (sepsis) organ failure assessment (SOFA) scoring, pediatric logistic organ dysfunction score-2 (PELOD-2), pediatric early warning system (PEWS), and iterations of the pediatric index of mortality (currently PIM3, used to bench-mark pediatric ICU performance) among others ( 5 ). A new definition of sepsis in children is planned for early 2024 ( 8 ), and the updated pediatric Surviving Sepsis Campaign International Guidelines remain a robust source of recommendations for management ( 9 ), including specific guidance to limit fluid bolus administration in settings without critical care capacity following the fluid expansion as supportive therapy (FEAST) trial in east African children ( 10 ).
pediatrics,critical care medicine
What problem does this paper attempt to address?